Sino Biopharmaceutical

LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

HanchorBio is a biotechnology research firm focused on developing innovative treatments for cancer. The company specializes in drug discovery that leverages tumor immunology, aiming to enhance the quality of life for cancer patients. By concentrating on cutting-edge research and development, HanchorBio seeks to revolutionize cancer treatment through its commitment to advancing therapeutic options.

Generon (Shanghai) Corporation Ltd. is an integrated biotech company developing therapeutic biologics for patients world-wide. Their research & development center is located in Zhang Jiang High-Tech Park, Shanghai, China. their cGMP drug manufacturing facility is located in Economic-Technological Development Area, Beijing, China. Their mission is “Innovating for Life” to develop innovative therapeutic biologics for global patients with unmet medical needs. They employ their proprietary, cutting-edge technology platforms to discover, develop and manufacture biologic therapeutics. They are focused on “best-in-class” and “first-in-class” recombinant therapeutic proteins to treat cancer, autoimmune and inflammatory diseases. They follow international quality standards for their product development and adhere to regulatory requirements of the CFDA, FDA and EMA. “Innovation and quality” are the soul of Generon in the generation of scientific data and in the processes of drug discovery, development and manufacturing.

Treadwell Therapeutics is a clinical-stage biotechnology company focused on developing innovative oncology therapeutics and small molecule drugs to meet the unmet needs of cancer patients. Founded in 2019 and based in New York, the company has established a robust pipeline that includes notable candidates such as CFI-400945, a first-in-class PLK4 kinase inhibitor, CFI-402257, a best-in-class TTK inhibitor, and CFI-402411, an oral immunomodulatory inhibitor targeting HPK1. Treadwell also engages in pre-clinical development of various biologic and next-generation TCR-based autologous cell therapy programs. With a team of experienced experts in drug discovery and clinical development, Treadwell aims to exploit cancer cell vulnerabilities and enhance recovery outcomes for patients.

XtalPi Inc. is a pharmaceutical technology company based in Cambridge, Massachusetts, with additional offices in China. Founded in 2014 by a team of quantum physicists from MIT, XtalPi focuses on transforming drug research and development through its Intelligent Digital Drug Discovery and Development (ID4) platform. This platform integrates quantum mechanics, artificial intelligence, and high-performance cloud computing to enhance the efficiency and accuracy of drug R&D processes. XtalPi's offerings include advanced tools for crystal structure prediction and determination, solid state testing, small molecule drug design, and AI model development. The company aims to accelerate drug discovery and development, thereby contributing to global health improvements. Its innovative technologies have garnered recognition within the industry and facilitated strategic partnerships with leading pharmaceutical companies.

Softhale is a medical device company dedicated to developing Soft Mist Inhalation (SMI) devices designed for the effective delivery of pharmaceutical drugs to the lungs. The company's inhalable therapeutic devices utilize proprietary technical configurations to spray a propellant-free liquid formulation. This advanced delivery method allows medication to navigate the natural curve of the throat, offering patients the opportunity to inhale the medication more naturally. By ensuring that drugs reach deep into the lungs, Softhale aims to enhance respiratory treatments and provide relief for individuals suffering from chronic respiratory conditions.

Sinovac Life Sciences is a research-based company that conducts human vaccine research, development, manufacturing, and sales.

Akeso Biopharma, based in Zhongshan, China, operates as a contract research organization (CRO) specializing in the discovery and development of antibody and protein drugs. Founded in 2012, the company provides comprehensive CRO services to both domestic and international pharmaceutical clients, focusing on areas such as protein expression, antibody generation, assay development, and humanization. Akeso has developed an extensive biopharmaceutical research and development platform, with a robust product pipeline that includes over 30 drugs targeting cancers, autoimmune diseases, inflammation, and cardiovascular conditions. Among these, 17 drugs have progressed to clinical stages, including two first-in-class bi-specific antibody drugs. The company collaborates with various pharmaceutical firms to innovate and develop new drug candidates, establishing itself as a leader in the industry through its advanced facilities and expertise.

LifeBond Ltd. specializes in the development and manufacturing of absorbable bio-surgical medical devices aimed at enhancing tissue repair and improving patient recovery. The company's flagship product, LifeSeal, is designed to reinforce staple lines in bariatric and colorectal surgeries, helping to minimize complications such as leakage. Another key product, LifeMesh, is a self-fixating mesh intended for hernia repair, providing secure fixation and reducing post-surgical issues. LifeBond also focuses on the development of tissue adhesives and absorbable hemostats. Founded in 2006 and based in Caesarea, Israel, the company offers its innovative medical solutions across various international markets, including the United States, Europe, and China. Although LifeSeal and LifeMesh are currently investigational and not yet approved for sale, they represent significant advancements in addressing unmet surgical needs.